東元醫院PK 創源生技 : Preimplantation genetic screening (PGS)

東元殖醫學與基因診斷公司簽約【聯合報╱記者羅緗綸╱即時報導】 2013.12.02 03:45 pm 新竹縣竹北東元醫院發展生殖醫學，今天下午3點在縣長邱鏡淳見證下，與全球胚胎植入前遺傳基因診斷公司BlastoGen創辦人Barry Behr簽署合作。東元醫院發展生殖醫學，在竹縣成立國際生殖醫學中心，盼協助竹科人「好孕」，今天簽署將更進一步引進胚胎植入前遺傳基因篩檢技術，盼確保孕育優秀的下一代。【2013/12/02 聯合報】

Preimplantation genetic screening (PGS) is used to determine embryonic aneuploidy. Transferring of aneuploid embryos leads to universally undesired outcomes such as failed embryo implantation, miscarriage or birth of trisomic offspring. Therefore, during the IVF process, applying PGS allows for informed decisions regarding the ploidy of which embryo(s) to transfer. BlastoGen is now offering advanced Preimplantation Genetic Screening (PGS) with the latest OPTIMIZED technology using array Comparative Genomic Hybridization (aCGH). The primary advantage of aCGH is the ability to simultaneously detect aneuploidies, deletions, duplications and unbalanced translocations with a rapid turnaround. Array-CGH uses thousands of small segments of DNA as targets for each chromosome for analysis. BlastoGen has performed comprehensive validation with known karyotyped cells to produce high level of accuracy, reproducibility, sensitivity and specificity and is committed to the highest standards of integrity, quality and service.